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Introduction
Background. Human papillomavirus (HPV) is a family of 
viruses that infect epithelial tissues including skin, cervix, anus, 
mouth and throat.1,2 The primary path of transmission is sexual 
contact, although HPV can also be passed on vertically from 
mother to child.3 HPV infection may lead to anogenital warts, 
precancerous lesions and cervical cancer, and close to 100% of 
cervical cancers are caused by HPV infection.4 Worldwide, 493 
000 new cases of cervical cancer and 274 000 deaths due to the 
disease were reported in 2002, making it the second most com-
mon cancer in females.5
Two vaccines are currently available in the market. Gardasil®  
(Sanofi Pasteur MSD), a quadrivalent vaccine that protects 
against HPV types 6, 11, 16, and 18, holds an indication in indi-
viduals (males and females) aged 9 y and older for the prevention 
of premalignant genital (cervical, vulvar, and vaginal) lesions and 
cervical cancer and genital warts causally related to these HPV 
types.6 Another vaccine, Cervarix®  (GlaxoSmithKline) protects 
against HPV types 16 and 18 and is indicated for the prevention 
of premalignant genital (cervical, vulvar, and vaginal) lesions and 
cervical cancer causally related to certain oncogenic HPV types 
in females.7
Routine vaccination programs against HPV in females 
have been implemented and publicly funded in the majority of 
Western European countries to protect against the diseases, in 
addition to cervical screening campaigns.8
Context. The International Agency for Research on Cancer 
(IARC) has classified HPV as a human carcinogen at different 
anatomical sites beyond the cervix: penis, anus, oral cavity, 
oropharynx and tonsils.9 It is estimated that the virus is associated 
with 80% to 85% of anal cancers, 70% of vaginal cancers, 40% 
of vulvar cancers, 50% of penile cancers, and 20% to 60% of 
head and neck cancers.10-12 In Europe, men bear approximately 
30% of the overall HPV-related cancers (17 403 incident cases 
annually), mainly due to head and neck cancers (14 098 incident 
cases annually).8,13-15 Emerging evidence from Denmark,16 the 
US,17 and Australia18 highlights a significant increase in the 
incidence of HPV-related head and neck cancers in males. An 
increase in the incidence of anal cancer has also been reported 
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in several countries19-21 and HPV infection was found to be the 
major contributor.21
Genital warts, associated with HPV types 6 and 11 in 90% 
of cases, are very common and recurrent benign lesions.22,23 
Although they do not lead to life-threatening diseases, genital 
warts affect patients’ quality of life, especially due to emotional 
and sexual concerns.24,25 It is estimated that between 286 682 
and 325 722 new cases of genital warts occur annually among 
males in Europe as a consequence of HPV types 6 and 11 
infection.15
Female-only HPV vaccination protects heterosexual males 
indirectly via their partners, but these heterosexual men will 
remain vulnerable to HPV unless vaccinated. To provide direct 
protection to males, several countries recently recommended vac-
cinating males against HPV (Austria,26 Saxony in Germany,27 the 
US,28 Canada,29 and Australia30,31), in addition to female vaccina-
tion. The mass vaccination of boys is funded in the US,32 Prince 
Edward Island in Canada,33 Australia,30 Saxony in Germany,27 
and Vorarlberg in Austria.34
Issue and objective. Expanding the vaccination program to 
males would further control the transmission of HPV and pro-
vide direct protection to males. Yet the constraint on healthcare 
resources requires the program to be financially viable and more 
specifically, the value for money or cost-effectiveness of such a 
program needs to be assessed.
Past economic evaluations have concluded that vaccinating 
females is a cost-effective strategy whatever the country.35,36 This 
paper aimed to critically review published cost-effectiveness anal-
yses that assessed male HPV vaccination. It intended to (1) iden-
tify studies assessing the cost-effectiveness of male vaccination; 
(2) review the methods used for this assessment, and (3) identify 
the major drivers of cost-effectiveness of male vaccination and 
assess the consistency and robustness of the results.
Methods
Cost-effectiveness studies were identified through a pragmatic 
literature review conducted on PubMed from 1948 to 31st 
December 2011. The search strategy used was the following: 
“cost-benefit analysis” AND (“papillomavirus vaccines”[MeSH] 
OR HPV) AND (boys OR males). As a pragmatic review, we did 
not run the search on other electronic databases, which might 
lead to missing some potential studies. It is acknowledged as a 
limitation of the current study.
Titles and abstracts were screened and publications were 
excluded if they did not assess the cost-effectiveness of HPV vac-
cination in males. Selected papers were reviewed and information 
was extracted using a pre-specified summary table, (Table 1), 
which included the description of the modeling approach, model 
structure, main assumptions and parameterization.
A factor analysis was conducted in order to identify the major 
drivers of results as follows. The results of the sensitivity analyses 
from each study were reviewed and the magnitude and direction 
of change in the results were assessed where sufficient data were 
available. Given that both vaccination strategy and vaccine cover-
age rate strongly impact the level of protection and therefore the 
epidemiology of the disease, only sufficiently similar vaccination 
programs (in terms of vaccination coverage, target age, and sex) 
were used for this analysis.
Finally, the quality of the studies was also compared with the 
checklist suggested by Garnett et al.37 for mathematical models. 
The list of items is reproduced in Table 2.
Review
Overview. Fifty-eight citations were retrieved from the PubMed 
search. Two cost-effectiveness studies38,39 were excluded as they were 
very similar to another included study40 and did not focus on male 
vaccination. A total of nine cost-effectiveness studies that assessed 
male HPV vaccination were finally included in our review (Fig. 1). 
Six studies were conducted in the US context and the other three 
related to the UK, Austria, and Denmark. Quadrivalent vaccines, 
the only vaccine indicated in both sexes, were considered in all but 
two studies,41,42 which only looked at HPV types 16 and 18 in the 
analyses. All studies but one focused on heterosexual relationship. 
Kim43 specifically assessed the vaccination of men who have sex 
with men (MSM). Life year was used as the primary effectiveness 
endpoint in Zechmeister et al.,41 and in other studies health-related 
Table 1. Modeling aspects reviewed in this study
Aspects Descriptions
Modeling approach Dynamic vs. static; aggregate level vs. individual level; deterministic vs. stochastic.
Assumption on natural immunity
Susceptible-infectious-susceptible (SiS), susceptible-infectious-recovered (SiR) and susceptible-infectious-
recovered-susceptible (SiRS)a
Model calibration process Method used for calibration, if any.
Diseases modeled HPv-related diseases considered in the model.
HPV transmission patterns modeled Heterosexual or homosexual.
Vaccination and screening strategies 
assessed
vaccination strategy (initial vaccination, catch-up vaccination and booster), screening strategy and vaccine 
coverage rate.
Input parameters
vaccine characteristics (efficacy, against infection and/or disease, waning function), transition probabilities, 
costs, utilities and discount rate.
aAn SiR model assumes that, after recovery from infection, the individual will not be re-infected (i.e., natural immunity) whereas an SiS model assumes 
the individual can be re-infected immediately after recovery from infection (i.e., no natural immunity). An SiRS model assumes that natural immunity only 
exists for a period of time following recovery from infection.
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quality of life (measured by quality-adjusted life years [QALYs]) 
was used as the primary endpoint.
Only incremental cost-effectiveness ratios (ICERs) associated 
with the most similar strategies and vaccine coverage rate 
were reported in Table 3 to facilitate comparison. Yet, males’ 
vaccination is extremely interesting if coverage in females is sub-
optimal. These strategies compared male and female to female-
only vaccination strategies, except for Kim,43 which focused 
only on male vaccination. The coverage rate of the female only 
vaccination strategy was high (approximately 70%). Currencies 
were also converted to euros using the exchange rate in May 
201244 for comparative purposes.
Because vaccination strategies and comparators varied 
across studies, direct comparison of ICERs was not relevant. 
Nevertheless, the ICER results varied greatly among studies, 
ranging from €12 232 to €650 319 per QALY gained, a 53-fold 
increase. Two studies accounted for the prevention of HPV 16 
and 18 related cervical cancers only.41,42 The ICERs were high 
(approximate €300 000 per QALY or life-year gained) in both 
studies. In addition to the different comparators considered, such 
variation was most likely the result of significant differences in 
the design of the models.
The level of detail reported for each study varied greatly. Since 
most of the models are very complex, the lack of transparency 
makes it difficult to compare the different base case analyses.
Modeling methods and calibration approach. Four modeling 
methods were identified in the nine studies. Kim43 employed 
a standard static Markov cohort model. Kim and Goldie,47 
Taira et al.42 and Chesson et al.49 used hybrid models in which 
transmission of HPV and progression of HPV-related diseases 
were modeled separately. An agent-based model was used by 
Olsen and Jepsen.48 Although seldom used in the field of health 
economics,50,51 this type of model offers one of the most flexible 
approaches allowing individuals to act autonomously according 
to a set of if/then rules. Other studies were based on classical 
transmission models that utilized a set of differential equations 
to reflect the probability of infection as a function of the number 
of infected in the population of interest.
Due to the relatively low number of studies, it is difficult to 
investigate the structural uncertainty (i.e., impact of the choice of 
modeling method on the results).
Only two studies (Elbasha et al.40 and Chesson et al.49) 
derived parameters directly from existing literature whereas 
other studies estimated some parameters through a fitting 
procedure (i.e., calibration). A detailed description of the method 
of calibration was not reported in any of the studies. In some 
studies, such as Kim and Goldie,47 calibration targets were based 
Table 2. items that should accompany the most rigorous model analyses (reproduced with permission from Garnett et al.37)
Aspects Descriptions
Diagrams that show 
model structure
To show how disease natural history is presented, process and determinants of disease acquisition, and how putative 
intervention could affect the system.
Complete list of 
model parameters
To include clear and precise descriptions of the meaning of each parameter, together with the values or ranges for each, 
with justification or the primary source cited, and important caveats about the use of these values noted. where a parameter 
value comes from another modeling analysis, this caveat should be noted. Parameter values that are fit in this model (not 




illustration of agreement between model (as used in the analyses) and data or observational information. Clear statement 
about how model was fitted to the data, including goodness-of-fit measure, the numerical algorithm used, which parameter 
varied, constraints imposed on parameter values, and starting conditions.
Presentation  
of results
Key modeling results to be presented with a scientifically based estimate of uncertainty. Presentation of uncertainty analyses 
should be accompanied with statement about the sources of uncertainties quantified and not quantified, and these sources 
can include parameter, data, and model structure.
Discussion of model 
structure
To include the scientific rationale for this choice of model structure and identify points where this choice would influence 
conclusion drawn. Also to describe the strength of the scientific basis underlying the key model assumptions.
Figure 1. PRiSMA diagram.
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on epidemiological and clinical data from other countries, which 
could raise questions of data transferability.
HPV-related diseases considered. As reported in Table 1, 
only three studies (Elbasha and Dasbach,45 Kim and Goldie,47 
and Chesson et al.49) considered the full spectrum of HPV-
related diseases, i.e., anogenital diseases, head and neck cancers, 
recurrent respiratory papillomatosis (RRP) and genital warts.
Considering more diseases directly resulted in a decrease of the 
ICER as it accounted for the prevention of further HPV-related 
diseases (Fig. 2). Compared with cervical disease only (i.e., 
dynamic models only considered a reduction in the incidence of 
cervical cancer through indirect protection), considering the full 
spectrum of diseases reduced the ICER by 75.1% (from $741 280 
to $184 270 per QALY gained) in Chesson et al.,49 by 68.7% 
(from $290 290 to $90 870 per QALY gained) in Kim and 
Goldie,47 and by 86.9% (from $195 322 to $25 664 per QALY 
gained) in Elbasha and Dasbach.45 Genital warts alone accounted 
for more than half of the ICER reduction, as it is much more 
prevalent than other HPV-related diseases. When looking at 
the vaccination of MSM, Kim et al.43 reported that inclusion of 
genital warts in additional to anal cancer would reduce the ICER 
by approximately 20% (from $19 070 to $15 290 per QALY 
gained).
Conversely, none of the analyses explored the impact of 
changing epidemiological estimates of some HPV-related diseases 
and a constant incidence was used. As noted earlier, a significant 
increase was witnessed in the incidence of head and neck cancers in 
males and of anal cancer in both sexes.16-21 Disregarding such trend 
may have led to underestimating the benefits of vaccinating males.
Assumptions around natural immunity. In the studies, 
the assumption regarding natural immunity ranged from no 
immunity to full and lifelong immunity after the clearance of 
an episode of HPV infection. With no immunity, individuals 
become susceptible again immediately after the clearance of the 
infection, leading to an SIS (susceptible-infectious-susceptible) 
model structure. Similarly, full and lifelong immunity links to 
an SIR (susceptible-infectious-recovered) model and if immunity 
was assumed to wane and disappear an SIRS (susceptible-
infectious-recovered-susceptible) model was used.
Theoretically, the assumption around natural immunity will 
affect transmission parameters when they are calibrated. In most 
of the models, calibration targets included observed incidence of 
diseases associated with HPV and prevalence of HPV infection. 
An SIR model will require higher transmission rates than an SIS 
model to match the observed epidemiology, as a proportion of 
the population becomes naturally immune after infection and 
is therefore not contributing to the transmission of the disease. 
Hence, a higher natural immunity level mechanically predicts a 
lower vaccine effect (i.e., higher ICER). This was confirmed in 
Elbasha et al.,40 which reported a decrease of 74.3% in the ICER 
(from $45 056 to $11 567 per QALY gained; primary vaccination 
at 12 y with a catch-up campaign at the age of 12 to 24 y, in 
both sexes vs. in females) in ICER when the duration of natural 
immunity was reduced from lifelong to 10 y.
Vaccination strategies and coverage rate. In most of the 
studies, the primary vaccination was given to those aged 12 y 
for both females and males, except in Elbasha et al.,40 where 
individuals of 9 to 26 y old were vaccinated. In the MSM study, 
Kim43 assessed vaccination strategies at the age of 12, 20, or 26 
y old. Catch-up campaigns were explored in Elbasha et al.,40 Jit 
et al.46 and Olsen and Jepsen.48 The effect of booster vaccination 
was tested in Taira et al.42 and Zechmeister et al.41
Given the different ages (or age range) for the primary 
vaccination, catch-up vaccination or booster, there were limited 
scenarios that were comparable between studies.
Figure 2. HPv-related diseases and iCeRs. (A) 9–26 FM vs. 9–26F. Reprint-
ed with permission of elbasha and Dasbach.45 (B) 12FM vs. 12F. Reprinted 
with permission of Kim and Goldie.47 For cervical cancer plus genital 
warts, estimated from the graph in the publication. (C) 12FM+CU13–26F 
vs. 12F+CU13–26F. Reprinted with permission of Chesson et al.49 CC, cer-
vical cancer; vAG, vaginal cancer; vUL, vulvar cancer; PeN, penile cancer; 
ANA, anal cancer; H&N, head and neck cancers; JORRP, juvenile-onset 
RRP, recurrent respiratory papillomatosis; Gw, genital warts; F, female; M, 
male; CU, catch-up.
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The effect of the vaccine coverage rate on ICERs was tested 
in five studies (Elbasha et al.,40 Elbasha and Dasbach,45 Kim and 
Goldie,47 Taira et al.,42 and Chesson et al.49). As expected, the 
ICER of extending the vaccination to males increases with higher 
coverage rate of the existing vaccination program as a result of 
herd protection: the marginal benefit decreases when one more 
individual is vaccinated but the additional cost does not decrease. 
The impact of the coverage rate was found to be substantial. For 
instance, Chesson et al.49 reported that the ICER would increase 
from $23 649 to $41 379 per QALY gained when the coverage 
rate of the existing vaccination program increased from 20% to 
30%, with all diseases considered. If the coverage rate further 
increased to 75%, the ICER would quickly increase to $184 270 
per QALY gained (Fig. 3).
With regard to the vaccine coverage rate, most of the stud-
ies assumed a rate of around 70%. However, only Elbasha and 
Dasbach45 clearly stated that this was based on the observed data 
in the country of interest. Coverage assumptions in other studies 
might lead to inconsistency with the real world data and incor-
rect conclusion.
Vaccine price. Vaccine price varied between approximately 
€250 and €450 for a 3-dose course (including or excluding admin-
istration and wastage). Given the bulk procurement of HPV 
vaccines in many countries, the actual price would be expected 
to be lower than the list price due to negotiation or a tendering 
process. None of the studies accounted for this. In practice, the 
unit price of vaccines often decrease with time, especially given 
the timeframes of the analyses was relatively long (e.g., 100 y). 
Nevertheless this was not accounted for in any of the studies.
Four studies have tested the effect and sensitivity of the price 
in the context of overall cost-effectiveness (Elbasha et al.,40 Kim 
and Goldie,47 Kim,43 and Chesson et al.49). A linear relationship 
was seen between the proportional change in vaccine price and 
the proportional change in ICER.
Vaccine efficacy and protection duration. The base case 
assumptions on vaccine efficacy against infection came from 
clinical trial data and were numerically similar across studies. 
Only Elbasha et al.,40 Elbasha and Dasbach,45 Kim and Goldie,47 
and Kim43 considered efficacy against disease outcomes in 
addition to efficacy against HPV infection.
Most studies (except Elbasha et al.40 and Elbasha and 
Dasbach45) assumed that those protected by the vaccine could 
not transmit infection. Nevertheless, it may be possible that 
infections occurred in the vaccinated (without leading to disease) 
and whether these infections can be transmitted is unknown.52
The effect of vaccine efficacy on cost-effectiveness was not 
consistent in the four studies in which sensitivity analyses were 
conducted for this endpoint.40,42,47,49 This might be due to the 
effect of herd protection masking the benefit of higher efficacy.
Partial efficacy due to lack of compliance and duration of 
protection conferred by the vaccine were also studied in several 
publications. Their impact differed between studies.
Transition rates, disease costs and health-related quality of 
life. Comparison of transition rates between studies was difficult 
because of different assumptions on HPV transmission and disease 
progression or regression. This is further complicated by the fact 
that some rates were estimated in the calibration process, which 
was not well described and also heterogeneous between studies.
Disease costs were generally similar across studies, except for 
genital warts, which were consistently lower in European studies 
(Table 4). Costs were often limited to direct medical costs and 
did not take into account certain costs such as those associated 
with functional and psychological sequelae of treatment and psy-
chological impact of HPV-related morbidities.53-61
For health-related quality of life, additive (i.e., using utility 
decrements) or multiplicative (i.e., using utility multiplier) meth-
ods were used in different studies (Table 5). The health-state 
utility values or weights were largely consistent across studies as 
the primary studies on this topic were limited. The major differ-
ence was seen in the assumption of the duration of the disutility 
associated with genital warts: 3 mo in Kim and Goldie,47 8.5 mo 
in Elbasha and Dasbach,45 and 6 mo in Chesson et al.49 Given 
the prevalence of genital warts, such an assumption could have a 
significant impact and help explain the different results between 
studies. Difference was also seen in the treatment of quality of life 
in cured cancer patients. As long-term consequences have detri-
mental effects in these patients, many studies considered a lower 
utility value for them, although methods differed.
Rigor of the studies. The assessment of the quality of each 
study is reported in Table 6, using the checklist suggested by 
Garnett et al.37 Most of the studies did not discuss the model 
structure, the implications of using the selected model structure 
or the possible results if using an alternative one. Although cali-
bration has been conducted in numerous studies, there was a gen-
eral lack of transparency regarding how it was performed, what 
targets and variables were used and the comparison between the 
model prediction and the observation.
Discussion
A pragmatic critical literature review of published cost-
effectiveness analyses that assessed male HPV vaccination was 
performed and nine studies were reviewed. Six were conducted 
Figure 3. vaccine coverage rate and iCeRs. 12FM+CU13–26F vs. 
12F+CU13–26F. Reprinted with permission of Chesson et al.49
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in the US context, and all except one focused on heterosexual 
relationships.
When considering extending the female-only vaccination 
strategy to males in an environment where female vaccination 
coverage of around 70%, the ICER ranged from €12 232 to €650 
319 per QALY gained. Nevertheless direct comparison of ICERs 
was not appropriate due to vast heterogeneity among studies, in 
terms of modeling approach, assumptions around natural immu-
nity, vaccination strategy, vaccine coverage rate, whether most 
HPV-related diseases were accounted for, and other inputs.
The factor analysis was not able to investigate the absolute 
levels of ICER associated with male vaccination because of the 
fundamental difference among models. One of the main drivers 
was which of the HPV-related diseases considered. The ICER 
decreased with more diseases considered; this type of analysis 
more accurately captures all benefits of vaccination. Genital 
warts were found to have the largest impact on the assessment 
of the quadrivalent vaccine. A shortened duration of natural 
immunity contributed to an improved ICER but this was only 
assessed in one of the cost-effectiveness studies. Vaccination 
strategy and coverage rate also played an important role. With 
more females vaccinated through catch-up campaigns or with a 
higher coverage rate, the ICER spiked as the marginal benefit 
decreased. Lastly, the ICER was almost directly proportionally 
to vaccine price.
The reporting of the analyses was not very detailed across 
studies and it led to a lack of transparency. The main issues 
related to the lack of justification for the selected modeling 
approach and the lack of transparency regarding the calibration 
process. More scenarios and sensitivity analyses could 
contribute to a better understanding of the impact of each 
parameter on the results. Recently, the International Society for 
Pharmacoeconomics and Outcomes Research and the Society 
for Medical Decision Making published recommendations on 
the best practice for transparency and validity. It includes the 
report of ‘nontechnical’ description (e.g., type of the model, 
inputs, outputs and other parameters, data selection), technical 
documentation that allows audience with necessary expertise 
to evaluation and potentially reproduce the analysis, and 
information on the face, internal, cross, external and predictive 
validity. These recommendations could be considered and 
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In 2012, the European Centre for Disease Prevention and 
Control (ECDC) published a report on HPV vaccination, with 
a special focus on male vaccination.63 Although the ECDC 
recognized the high burden related to HPV in males, the report 
noted that the analyses were not fully evidence-based and 
concluded that vaccination of males was unlikely to be cost-
effective in the current economic conditions. The current study 
took a different angle. We tried to identify the major drivers of 
difference in results seen across studies, but as for the absolute 
cost-effectiveness, very limited conclusions could be drawn due 
to vast heterogeneity of the approach.
Following the review, several methodological concerns and 
suggestions for future studies were raised.
First and foremost, an optimal modeling approach could not 
be recommended based on the review nor from the literature. 
However, a key methodological question concerns the degree of 
complexity a model should include. Most models incorporated 
an advanced design, program, and parameterization. But with 
even the most detailed aspects considered, would there be enough 
data to populate the model? As the review shows, many studies 
utilized sources from other countries or even other continents, 
and yet the calibration process and the extent that the estimated 
parameters fit the observations were either unreported or under-
reported. Interestingly, in the official Australian assessment of 
male HPV vaccination, a positive conclusion was reached with 
a simple model, even though few details were made available.64 
An alternative to using complex models may be to focus more 
on factors that substantially affect the conclusion. Few studies 
discussed structural uncertainty in detail and many assumptions 
were made in the absence of empirical evidence. Methods to 
tackle this type of uncertainty were discussed but universal 
agreement has not been reached.65-67
Second, transparency should be improved in future studies. 
It is recognized that it would be difficult to clearly report all 
aspects of a complex model in a short publication. Nevertheless, 
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uncertainties should be tested whenever possible (e.g., reported 
in appendices). For instance, the assumption around natural 
immunity was only tested in Elbasha et al.,40 and it is unclear 
whether the results were coincidental. Fortunately, evidence is 
available from two other epidemiological studies. Baussano et al.68 
assessed the effect of vaccinating 12-y old girls in an unscreened 
environment. The authors reported that the SIS model predicted a 
reduction in lifetime incidence of cervical cancer of 16% and 21% 
higher than the SIR model in the unvaccinated and vaccinated 
cohorts. This difference could be increased up to 30% with 
alternative clinical assumptions and vaccination strategy. Similar 
findings were also reported by Van de Velde et al. (2010).69 The 
alternative assumption on this, nevertheless, was not tested in other 
cost-effectiveness studies. Its impact therefore remains uncertain.
The third point relates to the use of real life data. Only Elbasha 
and Dasbach45 utilized real life vaccine coverage data. Regarding 
price of vaccination, as it is common to procure vaccines in bulk 
for national programs, price negotiation or tendering processes 
are very likely to reduce the actual price of the vaccine.70,71 With 
many factors affecting the cost-effectiveness profile based on 
assumptions, the validity of the results is subject to question. 
Additionally, not accounting for observed epidemiological trends 
(e.g., of anal cancer and head and neck cancers16-21) and evolving 
sexual behavior may have further biased the results.
Fourthly, the lack of data to support parameterization of 
economic analyses has been witnessed throughout the review. For 
example, while genital warts contribute to a great proportion of 
HPV-related disease burden, the utility multiplier of genital warts 
in most of the studies came from a single conference abstract.72 
Without further scrutiny of the method and compatibility of 
settings and measurement, the use of such a source may introduce 
additional uncertainties to the analyses. Additional studies on 
the transmission of the infection, the disease, costs and health-
related quality of life are needed to enhance the robustness of 
future economic assessments.
Lastly, HPV vaccination is a public health intervention and 
its benefits will only be realized years or decades after the imple-
mentation of the program. An equity concern is therefore raised: 
should we discount the benefit of future generations? There is not 
yet a consensus on this topic despite extended debates.73 Further 
to this point, aspects such as the incorporation of outcome- and 
behavior-related productivity benefits,74 the utility in anticipation 
(i.e., the increase in utility associated with the knowledge of being 
protected from the time of vaccination)75 have been raised in the 
context of assessing public health intervention. Nevertheless no 
consensus has yet been reached.
Conclusion
A total of nine cost-effectiveness studies of male HPV vacci-
nation have been reviewed. Due to the heterogeneity among the 
studies, limited conclusions could be drawn with regard to the 
absolute cost-effectiveness of male vaccination.
However it was found that incorporation of all HPV-related 
diseases and a suboptimal vaccine coverage rate among girls 
could improve the cost-effectiveness profile of male vaccination.
Table 6. Rigor of the studies
Studies Diagram
Complete list of model 
parameters













ing number of 
items























Kim43 No No Not calibrated No sensitivity analyses No 0/5


























Based on published 
literatures
Yes No 3/5
*Sensitivity analyses are conducted for vaccine parameters, cost and utilities. Natural history parameters such as the probability of transmission are not 
included in sensitivity analyses. Cross-protection has been included in some sensitivity analyses. SA, sensitivity analyses; PSA, probabilistic sensitivity 
analyses.
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Most of the studies did not provide sufficient transparency 
on the assumptions and calibration process (where conducted), 
yet fewer studies tested the alternative assumption, such as 
the natural history of HPV infection and protection duration 
of the vaccine. Some key factors such as vaccine coverage rate 
and vaccine price were largely based on assumptions, poten-
tially leading to biased results. None of the studies considered 
the epidemiological trend of HPV-related diseases, such as the 
observed increase in the incidence of anal and head and neck 
cancers.
Future research should be conducted to better understand 
the disease, as well as to provide costs and health-related 
quality of life data for economic analysis. Methodologically, the 
selection of modeling approach and the aspects to be considered 
for the assessment of public health policy, especially how the 
true economic value of vaccination is captured beyond cost-
effectiveness results, need further discussion and consensus.
Disclosure of Potential Conflicts of Interest
This study was conducted by Amaris and funded by Sanofi 
Pasteur MSD. Yiling Jiang and Aline Gauthier are employees 
of Amaris, which received consulting fees from Sanofi Pasteur 
MSD and GlaxoSmithKline. Maarten J. Postma has received 
grants from Sanofi Pasteur MSD and GlaxoSmithKline. Laureen 
Ribassin-Majed has received consulting fees from Sanofi Pasteur 
MSD. Nathalie Largeron and Xavier Bresse are employees 
of Sanofi Pasteur MSD. The authors have no other relevant 
affiliations or financial involvement with any organization or 
entity with a financial interest or financial conflict with the 
subject matter or materials discussed in the manuscript apart 
from those disclosed.
Acknowledgments
The authors would like to thank Marjorie Adam (an employee 
of Sanofi Pasteur MSD), Marine Clementz and Carl Selya-
Hammer (employees of Amaris) for critically reviewing and 
providing inputs for the manuscript.
References
1. Schiller JT, Day PM, Kines RC. Current understanding 
of the mechanism of HPV infection. Gynecol Oncol 
2010; 118(Suppl):S12-7; PMID:20494219; http://
dx.doi.org/10.1016/j.ygyno.2010.04.004
2. Longworth MS, Laimins LA. Pathogenesis of human 
papillomaviruses in differentiating epithelia. Microbiol 
Mol Biol Rev 2004; 68:362-72; PMID:15187189; 
http://dx.doi.org/10.1128/MMBR.68.2.362-372.2004
3. Bonnez W, Reichman RC. Papillomaviruses. In: 
Mandell GL, Bennett JE, Dolin R, eds. Principles 
and practice of infectious diseases. Philadelphia, PA: 
Churchill Livingstone Elsevier, 2010:2035-2049.
4. Saslow D, Castle PE, Cox JT, Davey DD, Einstein 
MH, Ferris DG, et al.; Gynecologic Cancer Advisory 
Group. American Cancer Society Guideline for human 
papillomavirus (HPV) vaccine use to prevent cervical 
cancer and its precursors. CA Cancer J Clin 2007; 
57:7-28; PMID:17237032; http://dx.doi.org/10.3322/
canjclin.57.1.7
5. Parkin DM, Bray F. Chapter 2: The burden of HPV-
related cancers. Vaccine 2006; 24 Suppl 3:S3-11-S3/25.
6. European Medicines Agency. Gardasil: EPAR - prod-
uct information. 31 July 2012. Available at http://
www.ema.europa.eu/docs/en_GB/document_library/
EPAR_-_Product_Information/human/000703/
WC500021142.pdf, accessed 14 June 2013.
7. European Medicines Agency. Cervarix: sum-
mary of opinion (post-authorisation). 21 February 
2013. Available at http://www.ema.europa.eu/docs/
en_GB/document_library/Summary_of_opinion/
human/000721/WC500139202.pdf, accessed 14 June 
2013.
8. Bonanni P, Levi M, Latham NB, Bechini A, Tiscione 
E, Lai P, et al. An overview on the implementation 
of HPV vaccination in Europe. Hum Vaccin 2011; 
7(Suppl):128-35; PMID:21245659; http://dx.doi.
org/10.4161/hv.7.0.14575
9. IARC Working Group on the Evaluation of Carcinogenic 
Risks to Humans. Human papillomaviruses. IARC 
Monogr Eval Carcinog Risks Hum 2007; 90:1-636; 
PMID:18354839
10. De Vuyst H, Clifford GM, Nascimento MC, Madeleine 
MM, Franceschi S. Prevalence and type distribution of 
human papillomavirus in carcinoma and intraepithelial 
neoplasia of the vulva, vagina and anus: a meta-analysis. 
Int J Cancer 2009; 124:1626-36; PMID:19115209; 
http://dx.doi.org/10.1002/ijc.24116
11. Giuliano AR, Tortolero-Luna G, Ferrer E, Burchell 
AN, de Sanjose S, Kjaer SK, et al. Epidemiology 
of human papillomavirus infection in men, cancers 
other than cervical and benign conditions. Vaccine 
2008; 26(Suppl 10):K17-28; PMID:18847554; http://
dx.doi.org/10.1016/j.vaccine.2008.06.021
12. Gillison M. HPV and its effect on head and neck 
cancer prognosis. Clin Adv Hematol Oncol 2010; 
8:680-2; PMID:21317864
13. Syrjänen S, Lodi G, von Bültzingslöwen I, Aliko A, 
Arduino P, Campisi G, et al. Human papillomavi-
ruses in oral carcinoma and oral potentially malig-
nant disorders: a systematic review. Oral Dis 2011; 
17(Suppl 1):58-72; PMID:21382139; http://dx.doi.
org/10.1111/j.1601-0825.2011.01792.x
14. Goon PK, Stanley MA, Ebmeyer J, Steinsträsser L, 
Upile T, Jerjes W, et al. HPV & head and neck cancer: 
a descriptive update. Head Neck Oncol 2009; 1:36; 
PMID:19828033; http://dx.doi.org/10.1186/1758-
3284-1-36
15. Hartwig S, Syrjänen S, Dominiak-Felden G, Brotons 
M, Castellsagué X. Estimation of the epidemiological 
burden of human papillomavirus-related cancers and 
non-malignant diseases in men in Europe: a review. 
BMC Cancer 2012; 12:30; PMID:22260541; http://
dx.doi.org/10.1186/1471-2407-12-30
16. Blomberg M, Nielsen A, Munk C, Kjaer SK. Trends 
in head and neck cancer incidence in Denmark, 1978-
2007: focus on human papillomavirus associated sites. 
Int J Cancer 2011; 129:733-41; PMID:20878955; 
http://dx.doi.org/10.1002/ijc.25699
17. Marur S, D’Souza G, Westra WH, Forastiere AA. 
HPV-associated head and neck cancer: a virus-related 
cancer epidemic. Lancet Oncol 2010; 11:781-9; 
PMID:20451455; http://dx.doi.org/10.1016/S1470-
2045(10)70017-6
18. Hocking JS, Stein A, Conway EL, Regan D, Grulich 
A, Law M, et al. Head and neck cancer in Australia 
between 1982 and 2005 show increasing incidence of 
potentially HPV-associated oropharyngeal cancers. Br 
J Cancer 2011; 104:886-91; PMID:21285981; http://
dx.doi.org/10.1038/sj.bjc.6606091
19. Brewster DH, Bhatti LA. Increasing incidence of 
squamous cell carcinoma of the anus in Scotland, 1975-
2002. Br J Cancer 2006; 95:87-90; PMID:16721368; 
http://dx.doi.org/10.1038/sj.bjc.6603175
20. Jin F, Stein AN, Conway EL, Regan DG, Law 
M, Brotherton JM, et al. Trends in anal cancer 
in Australia, 1982-2005. Vaccine 2011; 29:2322-
7; PMID:21255682; http://dx.doi.org/10.1016/j.
vaccine.2011.01.015
21. Nielsen A, Munk C, Kjaer SK. Trends in incidence 
of anal cancer and high-grade anal intraepithelial 
neoplasia in Denmark, 1978-2008. Int J Cancer 
2012; 130:1168-73; PMID:21469144; http://dx.doi.
org/10.1002/ijc.26115
22. von Krogh G; von KG. Management of anogenital 
warts (condylomata acuminata). Eur J Dermatol 2001; 
11:598-603, quiz 604; PMID:11701422
23. Lacey CJ, Lowndes CM, Shah KV. Chapter 4: Burden 
and management of non-cancerous HPV-related con-
ditions: HPV-6/11 disease. Vaccine 2006; 24 Suppl 
3:S3-35-S3/41.
24. Maw RD, Reitano M, Roy M. An international survey 
of patients with genital warts: perceptions regard-
ing treatment and impact on lifestyle. Int J STD 
AIDS 1998; 9:571-8; PMID:9819106; http://dx.doi.
org/10.1258/0956462981921143
25. Woodhall S, Ramsey T, Cai C, Crouch S, Jit M, Birks 
Y, et al. Estimation of the impact of genital warts 
on health-related quality of life. Sex Transm Infect 
2008; 84:161-6; PMID:18339658; http://dx.doi.
org/10.1136/sti.2007.029512
26. Bundesministerium für Gesundheit. Impfplan 
Österreich 2013. Evidenz-basierte Empfehlungen des 
Nationalen Impfgremiums. 2013. Available at http://
bmg.gv.at/cms/home/attachments/3/3/6/CH1100/
CMS1327680589121/impfplan2013.pdf, accessed 14 
June 2013.
27. Landesärztekammer S. Empfehlungen der 
Sächsischen Impfkommission zur Durchführung von 
Schutzimpfungen im Freistaat Sachsen. 1 January 2013. 
Available at http://www.slaek.de/de/03/36impfen/pdf/
E1_2013_Druck.pdf, accessed 14 June 2013.
28. Centers for Disease Control and Prevention (CDC). 
Recommendations on the use of quadrivalent 
human papillomavirus vaccine in males--Advisory 
Committee on Immunization Practices (ACIP), 2011. 
MMWR Morb Mortal Wkly Rep 2011; 60:1705-8; 
PMID:22189893
29. National Advisory Committee on Immunization. 
Update on human papillomavirus (HPV) vaccines. 
Can Commun Dis Rep 2012; 38:1-62
30. Department of Health and Ageing. HPV vaccine 
extended to boys. 2012. Available at http://www.
health.gov.au/internet/ministers/publishing.nsf/Conte
nt/59C397F61CACF02FCA257A390000C65A/$Fi
le/TP059.pdf, accessed 14 June 2013.
www.landesbioscience.com Human vaccines & immunotherapeutics 2295
31. Department of Health and Ageing. Fact sheet. National 
Immunisation Program - HPV vaccination for boys. 
2012. Available at http://www.health.gov.au/internet/
immunise/publishing.nsf/Content/1958E1814219368
8CA2575BD001C80CA/$File/HPV-vaccination-for-
boys-factsheet.pdf, accessed 14 June 2013.
32. Centers for Disease Control and Prevention. The 
VFC program: at a glance. 31 August 2012. Available 
at http://www.cdc.gov/vaccines/programs/vfc/about/
index.html, accessed 14 June 2013.
33. Prince Edward Island Department of Health and 
Wellness. HPV vaccine program expands to include 
boys. 18 April 2013. Available at http://www.gov.pe.ca/
health/index.php3?number=news&dept=&newsnumb
er=8937&lang=Econtent, accessed 14 June 2013.
34. Vorarlberg L. Verbesserung der Gesundheitsvorsorge 
für Jugendliche. HPV-Impfung wird deutlich billiger. 
24 January 2013. Available at http://www.vorarlberg.
at/doc/hpv_pku.doc, accessed 14 June 2013.
35. Marra F, Cloutier K, Oteng B, Marra C, Ogilvie G. 
Effectiveness and cost effectiveness of human papilloma-
virus vaccine: a systematic review. Pharmacoeconomics 
2009; 27:127-47; PMID:19254046; http://dx.doi.
org/10.2165/00019053-200927020-00004
36. Seto K, Marra F, Raymakers A, Marra CA. The cost effec-
tiveness of human papillomavirus vaccines: a system-
atic review. Drugs 2012; 72:715-43; PMID:22413761; 
http://dx.doi.org/10.2165/11599470-000000000-
00000
37. Garnett GP, Cousens S, Hallett TB, Steketee R, 
Walker N. Mathematical models in the evaluation 
of health programmes. Lancet 2011; 378:515-25; 
PMID:21481448; http://dx.doi.org/10.1016/S0140-
6736(10)61505-X
38. Insinga RP, Dasbach EJ, Elbasha EH, Puig A, Reynales-
Shigematsu LM. Cost-effectiveness of quadrivalent 
human papillomavirus (HPV) vaccination in Mexico: a 
transmission dynamic model-based evaluation. Vaccine 
2007; 26:128-39; PMID:18055075; http://dx.doi.
org/10.1016/j.vaccine.2007.10.056
39. Kulasingam S, Connelly L, Conway E, Hocking JS, 
Myers E, Regan DG, et al. A cost-effectiveness analysis 
of adding a human papillomavirus vaccine to the 
Australian National Cervical Cancer Screening Program. 
Sex Health 2007; 4:165-75; PMID:17931529; http://
dx.doi.org/10.1071/SH07043
40. Elbasha EH, Dasbach EJ, Insinga RP. Model for 
assessing human papillomavirus vaccination strategies. 
Emerg Infect Dis 2007; 13:28-41; PMID:17370513; 
http://dx.doi.org/10.3201/eid1301.060438
41. Zechmeister I, Blasio BF, Garnett G, Neilson AR, 
Siebert U. Cost-effectiveness analysis of human pap-
illomavirus-vaccination programs to prevent cervi-
cal cancer in Austria. Vaccine 2009; 27:5133-41; 
PMID:19567244; http://dx.doi.org/10.1016/j.vac-
cine.2009.06.039
42. Taira AV, Neukermans CP, Sanders GD. Evaluating 
human papillomavirus vaccination programs. Emerg 
Infect Dis 2004; 10:1915-23; PMID:15550200; 
http://dx.doi.org/10.3201/eid1011.040222
43. Kim JJ. Targeted human papillomavirus vaccination 
of men who have sex with men in the USA: a cost-
effectiveness modelling analysis. Lancet Infect Dis 
2010; 10:845-52; PMID:21051295; http://dx.doi.
org/10.1016/S1473-3099(10)70219-X
44. XE.com. Universal currency converter. 19 September 
2012. Available at http://www.xe.com, accessed 19 
September 2012.
45. Elbasha EH, Dasbach EJ. Impact of vaccinating boys 
and men against HPV in the United States. Vaccine 
2010; 28:6858-67; PMID:20713101; http://dx.doi.
org/10.1016/j.vaccine.2010.08.030
46. Jit M, Choi YH, Edmunds WJ. Economic evaluation 
of human papillomavirus vaccination in the United 
Kingdom. BMJ 2008; 337:a769; PMID:18640957; 
http://dx.doi.org/10.1136/bmj.a769
47. Kim JJ, Goldie SJ. Cost effectiveness analysis of 
including boys in a human papillomavirus 
vaccination programme in the United States. BMJ 
2009; 339:b3884; PMID:19815582; http://dx.doi.
org/10.1136/bmj.b3884
48. Olsen J, Jepsen MR. Human papillomavirus 
transmission and cost-effectiveness of introducing 
quadrivalent HPV vaccination in Denmark. 
Int J Technol Assess Health Care 2010; 26:183-
91; PMID:20392322; http://dx.doi.org/10.1017/
S0266462310000085
49. Chesson HW, Ekwueme DU, Saraiya M, Dunne 
EF, Markowitz LE. The cost-effectiveness of male 
HPV vaccination in the United States. Vaccine 
2011; 29:8443-50; PMID:21816193; http://dx.doi.
org/10.1016/j.vaccine.2011.07.096
50. Bonabeau E. Agent-based modeling: methods and tech-
niques for simulating human systems. Proc Natl Acad 
Sci U S A 2002; 99(Suppl 3):7280-7; PMID:12011407; 
http://dx.doi.org/10.1073/pnas.082080899
51. Kim SY, Goldie SJ. Cost-effectiveness analyses of 
vaccination programmes: a focused review of mod-
elling approaches. Pharmacoeconomics 2008; 
26:191-215; PMID:18282015; http://dx.doi.
org/10.2165/00019053-200826030-00004
52. Regan DG, Philp DJ, Waters EK. Unresolved ques-
tions concerning human papillomavirus infection and 
transmission: a modelling perspective. Sex Health 
2010; 7:368-75; PMID:20719229; http://dx.doi.
org/10.1071/SH10006
53. Allal AS, Sprangers MA, Laurencet F, Reymond MA, 
Kurtz JM. Assessment of long-term quality of life 
in patients with anal carcinomas treated by radio-
therapy with or without chemotherapy. Br J Cancer 
1999; 80:1588-94; PMID:10408404; http://dx.doi.
org/10.1038/sj.bjc.6690567
54. de Graeff A, de Leeuw JR, Ros WJ, Hordijk GJ, 
Blijham GH, Winnubst JA. Long-term quality of life 
of patients with head and neck cancer. Laryngoscope 
2000; 110:98-106; PMID:10646723; http://dx.doi.
org/10.1097/00005537-200001000-00018
55. Jeffreys M, Rachet B, McDowell S, Habib AG, Lepage 
C, Coleman MP. Survival from rectal and anal cancers 
in England and Wales, 1986-2001. Eur J Cancer 
2006; 42:1434-40; PMID:16600590; http://dx.doi.
org/10.1016/j.ejca.2006.01.019
56. Maddineni SB, Lau MM, Sangar VK. Identifying the 
needs of penile cancer sufferers: a systematic review 
of the quality of life, psychosexual and psychosocial 
literature in penile cancer. BMC Urol 2009; 9:8; 
PMID:19664235; http://dx.doi.org/10.1186/1471-
2490-9-8
57. Pirotta M, Ung L, Stein A, Conway EL, Mast 
TC, Fairley CK, et al. The psychosocial burden of 
human papillomavirus related disease and screen-
ing interventions. Sex Transm Infect 2009; 85:508-
13; PMID:19703844; http://dx.doi.org/10.1136/
sti.2009.037028
58. Bray F, Klint A, Gislum M, Hakulinen T, Engholm 
G, Tryggvadóttir L, et al. Trends in survival of patients 
diagnosed with male genital cancers in the Nordic 
countries 1964-2003 followed up until the end of 
2006. Acta Oncol 2010; 49:644-54; PMID:20151937; 
http://dx.doi.org/10.3109/02841860903575315
59. Marur S, D’Souza G, Westra WH, Forastiere AA. 
HPV-associated head and neck cancer: a virus-relat-
ed cancer epidemic. Lancet Oncol 2010; 11:781-9; 
PMID:20451455; http://dx.doi.org/10.1016/S1470-
2045(10)70017-6
60. Arbyn M, Castellsagué X, de Sanjosé S, Bruni L, 
Saraiya M, Bray F, Ferlay J. Worldwide burden of 
cervical cancer in 2008. Ann Oncol 2011; 22:2675-86; 
PMID:21471563; http://dx.doi.org/10.1093/annonc/
mdr015
61. Mortensen GL, Paaske PB. Patients perceive tonsil 
cancer as a strike at psycho-socially “vital organs”. Dan 
Med J 2012; 59:A4504; PMID:22951199
62. Eddy DM, Hollingworth W, Caro JJ, Tsevat J, 
McDonald KM, Wong JB; ISPOR-SMDM Modeling 
Good Research Practices Task Force. Model transparency 
and validation: a report of the ISPOR-SMDM 
Modeling Good Research Practices Task Force-7. Med 
Decis Making 2012; 32:733-43; PMID:22990088; 
http://dx.doi.org/10.1177/0272989X12454579
63. European Centre for Disease Prevention and Control. 
Introduction of HPV vaccines in European Union 
countries – an update. September 2012. Available 
at http://ecdc.europa.eu/en/publications/publica-
tions/20120905_gui_hpv_vaccine_update.pdf, 
accessed 14 June 2013.
64. Department of Health and Ageing. Quadrivalent 
human papillomavirus (Types 6, 11, 16, 18) recombi-
nant vaccine, solution for injection, 0.5 mL, solution 
for injection pre-filled syringe single dose, Gardasil® . 
November 2011. Available at http://www.health.gov.
au/internet/main/publishing.nsf/Content/pbac-psd-
quadrivalent-nov11, accessed 14 June 2013.
65. Kim LG, Thompson SG. Uncertainty and validation of 
health economic decision models. Health Econ 2010; 
19:43-55; PMID:19206080
66. Jackson CH, Bojke L, Thompson SG, Claxton K, 
Sharples LD. A framework for addressing structural 
uncertainty in decision models. Med Decis Making 
2011; 31:662-74; PMID:21602487; http://dx.doi.
org/10.1177/0272989X11406986
67. Strong M, Oakley JE, Chicott J. Managing struc-
tural uncertainty in health economic decision models: 
a discrepancy approach. J R Stat Soc Ser C Appl Stat 
2012; 61:25-45; http://dx.doi.org/10.1111/j.1467-
9876.2011.01014.x
68. Baussano I, Garnett G, Segnan N, Ronco G, Vineis P. 
Modelling patterns of clearance of HPV-16 infection 
and vaccination efficacy. Vaccine 2011; 29:1270-7; 
PMID:21145375; http://dx.doi.org/10.1016/j.vac-
cine.2010.11.082
69. Van de Velde N, Brisson M, Boily MC. Understanding 
differences in predictions of HPV vaccine effective-
ness: A comparative model-based analysis. Vaccine 
2010; 28:5473-84; PMID:20573580; http://dx.doi.
org/10.1016/j.vaccine.2010.05.056
70. Garattini L, van de Vooren K, Curto A. Pricing 
human papillomavirus vaccines: lessons from Italy. 
Pharmacoeconomics 2012; 30:213-7; PMID:22233523; 
http://dx.doi.org/10.2165/11596560-000000000-
00000
71. Wallace LA, Young D, Brown A, Cameron JC, Ahmed 
S, Duff R, et al. Costs of running a universal ado-
lescent hepatitis B vaccination programme. Vaccine 
2005; 23:5624-31; PMID:16099079; http://dx.doi.
org/10.1016/j.vaccine.2005.06.034
72. Myers ER, Green S, Lipkus I. 542 Patient preferences 
for health states related to HPV infection: visual analog 
scales vs time trade-off elicitation. Proceedings of 21st 
International Papillomavirus Conference.
73. Weatherly H, Drummond M, Claxton K, Cookson R, 
Ferguson B, Godfrey C, et al. Methods for assessing 
the cost-effectiveness of public health interventions: 
key challenges and recommendations. Health Policy 
2009; 93:85-92; PMID:19709773; http://dx.doi.
org/10.1016/j.healthpol.2009.07.012
74. Bärnighausen T, Bloom DE, Cafiero ET, O’Brien JC. 
Economic evaluation of vaccination: capturing the full 
benefits, with an application to human papillomavirus. 
Clin Microbiol Infect 2012; 18(Suppl 5):70-6; 
PMID:22882176; http://dx.doi.org/10.1111/j.1469-
0691.2012.03977.x
75. Drummond M, Chevat C, Lothgren M. Do we fully 
understand the economic value of vaccines? Vaccine 
2007; 25:5945-57; PMID:17629362; http://dx.doi.
org/10.1016/j.vaccine.2007.04.070
